UTokyo's Innovation Platform joined subsidiaries of SBI, Sumitomo Mitsui and Mizuho Bank to help double genetic disorder treatment developer EdiGene's funding.

EdiGene, a Japan-based developer of genetic disorder treatments based on gene editing techniques, raised an initial ¥1.6bn ($15m) in series B funding yesterday from investors including University of Tokyo’s investment company UTokyo Innovation Platform. The round featured SBI Investment, SMBC Capital and Mizuho Capital – respective investment subsidiaries of financial services firms SBI Group, Sumitomo…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.